1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  05/25 04:00:01 pm EDT
3.240 USD   -0.31%
05/12CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/12TRANSCRIPT : CorMedix Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12CORMEDIX : Q1 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

11/04/2021 | 01:26pm EDT

Berkeley Heights, NJ - November 2, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021, and will host a corporate update conference call at 4:30pm Eastern Time.

Tuesday, November 9th @ 4:30pm ET

Domestic: 877-423-9813

International: 201-689-8573

Conference ID: 13723602

Webcast: Webcast Link

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the NDA received priority review in recognition of its potential to address an unmet medical need. QIDP provides for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The Company received a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract manufacturing facility, including in-process controls for the filling operation. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Disclaimer

CorMedix Inc. published this content on 02 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 November 2021 18:25:09 UTC.


© Publicnow 2021
All news about CORMEDIX INC.
05/12CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12TRANSCRIPT : CorMedix Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12CORMEDIX : Q1 Earnings Snapshot
AQ
05/12CORMEDIX INC. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
05/12CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
AQ
05/12CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12CorMedix Inc. Announces Leadership Updates and Operational Changes
AQ
05/12CorMedix Inc. Announces Executive Changes
CI
05/03CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Up..
AQ
04/07CorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipe..
AQ
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,64 M - -
Net income 2022 -36,5 M - -
Net cash 2022 118 M - -
P/E ratio 2022 -3,72x
Yield 2022 -
Capitalization 127 M 127 M -
EV / Sales 2022 14,3x
EV / Sales 2023 1,97x
Nbr of Employees 30
Free-Float 97,3%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,24 $
Average target price 22,00 $
Spread / Average Target 579%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-28.79%127
MERCK KGAA-22.27%81 684
KYOWA KIRIN CO. LTD.-12.79%11 611
SK BIOPHARMACEUTICALS CO., LTD.-10.08%5 298
YUHAN CORPORATION-3.86%3 181
BETTA PHARMACEUTICALS CO., LTD.-43.63%2 785